Cargando…

2656. Eliciting Preferences for Zoster Vaccination in US Adults Aged 50 Years and Older

BACKGROUND: In October 2017, the Centers for Disease Control and Prevention (CDC) recommended the adjuvanted Recombinant Zoster Vaccine (RZV) for all adults aged ≥ 50 years, regardless of previous vaccination. Understanding patient preferences for herpes zoster (HZ) vaccination can inform providers,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patterson, Brandon J, Meyers, Kelley, Stewart, Alexandra, Mange, Brennan, Hillson, Eric M, Cyr, Sonya, Poulos, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810089/ http://dx.doi.org/10.1093/ofid/ofz360.2334

Ejemplares similares

Patient and physician preferences for multiple sclerosis treatments in Germany: A discrete-choice experiment study
por: Poulos, Christine, et al.
Publicado: (2020)

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis
por: Poirrier, Jean-Etienne, et al.
Publicado: (2022)

2656. Longitudinal Trends in Attributable Causes of Death Among US Veteran Patients with Documented SARS-CoV-2 Infection between January 2021 and March 2023
por: Trottier, Caitlin A, et al.
Publicado: (2023)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

06. United States Healthcare Provider Preferences for Adult Pneumococcal Vaccine Recommendations
por: Vietri, Jeffrey, et al.
Publicado: (2021)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

PB2656: APPLICATION EFFECT OF TWO METHODS TO PREVENT SEVERE BLEEDING AT THE PUNCTURE POINT OF FEMORAL VEIN DIALYSIS TUBE IN PATIENTS WITH HEMATOLOGICAL DISEASES
por: Zhou, Xiaoqin, et al.
Publicado: (2023)

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US
por: Florea, Ana, et al.
Publicado: (2023)

Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States
por: Meyers, Juliana L., et al.
Publicado: (2017)

Efficacy is Not Everything: Eliciting Women’s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment
por: Browne, Erica N., et al.
Publicado: (2019)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

Eliciting Preferences on Secondary Findings: The Preferences Instrument for Genomic Secondary Results (PIGSR)
por: Brothers, Kyle B., et al.
Publicado: (2016)

A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome
por: Rashid, Muhammad U., et al.
Publicado: (2016)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France
por: Blein, Cecile, et al.
Publicado: (2015)

Risk of Herpes Zoster in Relation to Body Mass Index Among Residents Aged ≥50 Years: The Shozu Herpes Zoster Study
por: Kawahira, Kazuhiro, et al.
Publicado: (2022)

Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination
por: Poirrier, Jean-Etienne, et al.
Publicado: (2022)

Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study
por: Langan, Sinéad M., et al.
Publicado: (2013)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China
por: Zhu, Qi, et al.
Publicado: (2015)

Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2– Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656–2663
por: Pietropaolo, Massimo, et al.
Publicado: (2022)

Intracranial varicella zoster virus infection may elicit an unusual hyperkinetic volitional tremor
por: Shobatake, Ryogo, et al.
Publicado: (2020)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

Eliciting stakeholder preferences for patient-centered research
por: Mostofsky, Elizabeth, et al.
Publicado: (2019)

Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
por: Sacco, Patricia, et al.
Publicado: (2019)

Initial assessment and treatment of refugees in the Mediterranean Sea (a secondary data analysis concerning the initial assessment and treatment of 2656 refugees rescued from distress at sea in support of the EUNAVFOR MED relief mission of the EU)
por: Kulla, M., et al.
Publicado: (2016)

Eliciting preferences in glaucoma management—a systematic review of stated-preference studies
por: Scheres, L. M. J., et al.
Publicado: (2023)

Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above
por: Curran, Desmond, et al.
Publicado: (2018)

An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21
por: Nam, Hyo Jung, et al.
Publicado: (2022)

Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2018)

The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
por: Matthews, Sean, et al.
Publicado: (2019)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices
por: Boeri, Marco, et al.
Publicado: (2019)

Impact of discussion on preferences elicited in a group setting
por: Stein, Ken, et al.
Publicado: (2006)

On the role of monetary incentives in risk preference elicitation experiments
por: Hackethal, Andreas, et al.
Publicado: (2022)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pdurn5ljmrvhi7aua9f1dvh791